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Abstract
Background: Hsp90b is a member of the Hsp90 family of protein chaperones. This family plays essential roles in
the folding, maturation and activity of many proteins that are involved in signal transduction and transcriptional
regulation. The role of this protein in chondrocytes is not well understood, although its increase in osteoarthritic
cells has been reported. The present study aimed to explore the role of Hsp90b in key aspects of OA pathogenesis.
Methods: Human OA chondrocytes were isolated from cartilage obtained from patients undergoing joint
replacement surgery, and primary cultured. Cells were stimulated with proinflammatory cytokines (IL-1b or TNF-a)
and nitric oxide donors (NOC-12 or SNP). For Hsp90b inhibition, two different chemical inhibitors (Geldanamycin
and Novobiocin) were employed, or siRNA transfection procedures were carried out. Gene expression was
determined by real-time PCR, apoptosis was quantified by flow cytometry and ELISA, and nitric oxide (NO)
production was evaluated by the Griess method. Indirect immunofluorescence assays were performed to evaluate
the presence of Hsp90b in stimulated cells.
Results: Hsp90b was found to be increased by proinflammatory cytokines. Inhibition of Hsp90b by the chemicals
Geldanamycin (GA) and Novobiocin (NB) caused a dose-dependent decrease of the NO production induced by IL-
1b in chondrocytes, up to basal levels. Immunofluorescence analyses demonstrate that the NO donors NOC-12 and
SNP also increased Hsp90b. Chemical inhibition or specific gene silencing of this chaperone reduced the DNA
condensation and fragmentation, typical of death by apoptosis, that is induced by NO donors in chondrocytes.
Conclusions: The present results show how Hsp90b modulates NO production and NO-mediated cellular death in
human OA chondrocytes.
Background
Osteoarthritis (OA) is a slowly progressive degenerative
disease characterized by the degradation of the extracel-
lular matrix (ECM) and cell death, resulting in a gradual
loss of articular cartilage integrity, intra-articular inflam-
mation and changes in peri-articular and subchondral
bone [1]. The chondrocyte is the only cell type present
in mature cartilage and is responsible for repairing the
cartilage tissue damaged by OA.
Chondrocytes are key players in the control of carti-
lage matrix turnover through the production and
secretion of collagens, proteoglycans, and enzymes
affecting cartilage metabolism [2]. Chondrocyte metabo-
lism is influenced by several cytokines and growth fac-
tors, which drive two qualitatively distinct functional
programs in these cells: the catabolic program is
induced by proinflammatory stimuli and characterized
by the secretion of proteases, suppression of matrix
synthesis, and induction of chondrocyte apoptosis. The
anabolic program is associated with the secretion of
cytokines antagonistic to the catabolic program, synth-
esis of protease inhibitors, production of ECM, and cell
replication [3]. The balance between these processes is
essential for a proper tissue turnover, and efforts should
focus on this issue in order to gain a better understand-
ing on OA pathogenesis and be able to develop new
therapy strategies.
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Following this reasoning, we performed a differential
proteomic analysis in order to search for OA-related
changes in human articular chondrocyte intracellular
proteins, which aimed to unravel those molecular
mechanisms that participate in OA pathogenesis [4].
Among the proteins that were significantly altered in
OA chondrocytes, we identified the b subunit of the
chaperone Hsp90 as increased in diseased cells. This
increase was verified by immunodetection methods both
in OA chondrocytes and cartilage, and we found that
the proinflammatory cytokine IL-1b acts as a positive
modulator of Hsp90b abundance [4].
Hsp90b is a member of the Hsp90 family of protein
chaperones. This family plays essential roles in the fold-
ing, maturation and activity of many proteins that are
involved in signal transduction and transcriptional regu-
lation. Among the number of proteins that are known
to interact with Hsp90 are glucocorticoid receptors [5],
Akt/Protein kinase B and Raf-1 [6], the tumor suppres-
sor protein p53 [7] and NOS family members [8].
Despite being a family of proteins extensively studied in
other fields such as cancer [9], little is known about the
role of Hsp90 in chondrocyte biology. In the present
work we identify TNF-a and nitric oxide donors as
other positive modulators of Hsp90b, indicating a role
of this chaperone in mediating key processes that take
place in OA. Furthermore, we investigated the effect of
Hsp90b inhibition on nitric oxide production by these
cells, and found how knock-down of Hsp90b gene
expression with small interfering RNA (siRNA) reduces
NO-induced chondrocyte death.
Methods
Reagents
Culture media and fetal calf serum (FCS) were from
Gibco BRL (Paisley, UK). Culture flasks were purchased
from Costar (Cambridge, MA, USA). Unless indicated,
the rest of chemicals and enzymes were obtained from
Sigma-Aldrich (St. Louis, MO). Antibodies against
human Hsp90b (sc-1057), a-tubulin (sc-5286), the per-
oxidase-conjugated secondary antibodies and the FITC-
conjugated anti-goat secondary antibody were from
Santa Cruz Biotechnology (Sta. Cruz, CA, USA).
Cartilage procurement and processing
Macroscopically normal human knee cartilage from
adult donors from both genders (mean age 60.3 years;
age range 54-65 years) without history of joint disease
was provided by the Tissue Bank and the Autopsy Ser-
vice at Hospital Universitario A Coruña. Osteoarthritic
cartilage was obtained from patients diagnosed with OA
according to the American College of Rheumatology
(ACR) criteria, which underwent joint surgery (mean
age 64.6 years; age range 52-71 years). Knee radiographs
from the OA participants were classified as grade IV
according to the Kellgren and Lawrence (K/L) scoring
system. All patients have signed the informed consent
and the project was approved by the Regional Ethical
Committee from Galicia (Spain). Once cartilage surfaces
were rinsed with saline, scalpels were used to cut paral-
lel sections 5 mm apart, vertically from the cartilage sur-
face onto the subchondral bone. These cartilage strips
were then cut-off from this bone, and the tissue was
incubated with trypsin at 37°C for 10 minutes. After
removing trypsin solution, the cartilage slices were trea-
ted for 12-16 h with type IV clostridial collagenase in
Dulbecco’s modified Eagle’s medium (DMEM) with 5%
FCS in order to release cartilage cells.
Primary culture of chondrocytes
Chondrocytes were recovered and plated at high density
(4 × 106 per 162-cm2 flask) in DMEM supplemented
with 100 units/mL penicillin, 100 μg/mL streptomycin,
1% glutamine and 10% FCS. The cells were incubated at
37°C in a humidified gas mixture containing 5% CO2
balanced with air. Chondrocytes were used at weeks 2-3
at confluency in primary culture. Cell viability was
assessed by trypan blue dye exclusion.
Protein sample preparation
Chondrocytes (3-5 × 106 cells) were recovered from cul-
ture flasks by trypsinization and washed twice in a saline
buffer containing 130 mM NaCl, 5 mM KCl, 2.5 mM
Tris HCl (pH 7.5) and 0.7 mM Na2HPO4. Cells were
then transferred to microfuge tubes, where cell pellets
were solubilized by vortexing and one hour incubation
with gentle agitation in 200 μl of an isolectric focusing-
compatible lysis buffer containing 8.4 M urea, 2.4 M
thiourea, 5% cholamidopropyl diethylamoniopropane
sulfonate (CHAPS), 1% carrier ampholytes (IPG Buffer
pH 3-10 NL), 0.4% Triton X-100 and 2 mM dithiothrei-
tol (DTT).
For protein quantification, 10 μl of the protein extract
were diluted 10x with water and precipitated for at least
1 h with 0.02% sodium deoxycholate and 10% trichlor-
oacetic acid. The precipitate was washed once with 2
volumes of ice-cold acetone, allowed to dry, and solubi-
lized in alkaline SDS (5% SDS, 0.1 N NaOH). 5 to 10 μl
of this sample were employed to quantify total chondro-
cytic proteins in each lysate by the BCA technique
(Pierce Perbio, Rockford, IL, USA).
Cell viability assay
Cell viability was evaluated by Trypan blue dye exclu-
sion throughout the work. Nevertheless, due to the high
amount of NO accumulation observed in chondrocytes
after Novobiocin treatment, we decided to quantify cell
viability with a more accurate method in these
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experiments. The MTS [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazo-
lium, inner salt] assay was employed with this aim, using
the CellTiter 96® AQueous Non-Radioactive Cell Prolif-
eration Assay (Promega, Wisconsin, USA) kit and used
following the manufacturer’s instructions. Chondrocytes
were seeded into 96-well plates at a density of 2 × 103
per well (100 μl). This cell number was empirically
determined for our cells by performing a cell titration
assay. Briefly, human chondrocytes (0.5 × 103 - 1 × 104)
in DMEM supplemented with 10% FBS were seeded
onto a 96-well plate. The medium was allowed to equili-
brate for 24 hours, and then 10 μl of combined MTS/
PMS (phenazine methosulfate) solution were added to
each well. After 3 h at 37°C in a humidified, 5% CO2
atmosphere, the absorbance at 490nm was recorded
using an ELISA plate reader (Labsystems Multiskan Plus
Plate Reader). Once the optimal cell number was deter-
mined (near the low end of the linear range of the
assay), chondrocytes were treated with the following sti-
muli: vehicle control (DMEM), IL-1b 5 ng/mL, and
Novobiocin at 100, 500 and 1000 μmol/L in presence or
absence of IL-1b. Wells with serum-free medium were
used as negative control. The cells were treated for 48
h. 3 h before each of the desired time points, 10 μl of
the MTS reagent was added into each well and cells
were further incubated at 37°C. The absorbance was
detected at 490nm. All the experiments were repeated
four times.
Western blotting
Western blotting was performed according to standard
procedures. 20 μg of protein were loaded and resolved on
standard 10% polyacrylamide SDS-PAGE gels. Separated
proteins were then electroblotted onto polyvinylidene
difluoride membranes (Millipore Co, Bedford, MA,
USA). Equivalent loadings were verified by Ponceau Red
staining after transference. Membranes were blocked in
Tris-buffered saline, pH 7.4, containing 0.1% tween-20
(TBST), and 5% non-fat dried milk for 60 minutes at
room temperature. The blots were then hybridized over-
night at 4°C with antibodies against Hsp90b (1:1000), and
a-tubulin (1:5000). All antibodies were diluted in TBST
with 2% non-fat milk. After extensive washing with
TBST, immunoreactive bands were detected by chemilu-
miniscence using the correspondent peroxidase-conju-
gated secondary antibodies and ECL detection reagents
(GE Healthcare), and digitized using a LAS 3000 image
analyzer. Quantitative changes of protein were evaluated
with ImageQuant 5.2 software (GE Healthcare).
Induction and measurement of apoptosis
Apoptosis was induced by incubation of chondrocytes
with sodium nitroprusside (SNP), or N-ethyl-2-(1-ethyl-
2-hydroxy-2-nitrosohydrazine) ethanamine (NOC-12) at
0.5-1 mM in serum free DMEM for 24 hours. Cellular
DNA content was assessed as described previously by
flow cytometry [10]. For this purpose, 2 × 105 cells were
cultured in 6-well plates and treated as appropriate.
Then, cells were spun and resuspended in a solution
containing 1 mg/ml propidium iodide (PI) (Sigma) in
PBS. Then, they were incubated at 4°C for 30 minutes
in the dark and analyzed by flow cytometry on a FACS-
Calibur (BD Biosciences, San Jose, CA, USA) using a
560 nm dichromatic mirror and a 600 nm band pass fil-
ter. The percentage of cells with decreased DNA stain-
ing (composed of apoptotic cells resulting from either
fragmentation or decreased chromatin) of a minimum
of 10,000 cells per experimental condition was counted.
The data are expressed as the percentage of hypodiploid
(apoptotic) nuclei. Cells with a very low DNA content,
in which the type of cell death could not be ascertained,
were excluded from the analysis.
The apoptotic response was also measured in the
silencing experiments by Cell Death Detection ELISA-
PLUS (enzyme-linked immunosorbent assay) (Roche
Diagnostics, Mannheim, Germany, cat. N°
11774425001), following manufacturer’s instructions and
employing 2 × 104 cells seeded in 48-well plates. This
kit is used for the quantitative in vitro determination of
cytoplasmic histone-associated DNA fragments (mono-
and oligonucleosomes) after induced cell death.
Transfection of small interfering RNA (siRNA)
For the silencing experiments we used a pre-plated
transfection procedure. Approximately 72 hr before
transfection, 8 × 104 healthy adherent cells were trypsi-
nized and plated in 12-well plates, growing them in nor-
mal medium (DMEM, 10% FCS, 1% P/S, 1% gentamicin)
until they reach 80% confluency after 48 hr. Then, med-
ium was replaced with antibiotics-free DMEM. Cells
were transfected 24 hours later, following manufac-
turer’s instructions with minor modifications. Briefly, we
used 7 μL/mL of siPORT Amine Transfection Agent
(Ambion, cat. N° AM4502) and the final RNA concen-
tration was 30 nM for HSPCB Silencer® Validated
siRNA (Ambion, ref. AM51331). Controls were cells
transfected without siRNA. Preliminary experiments
determined that an incubation time of 72 h post-trans-
fection was required to obtain an optimal level of
HSPCB silencing. The transfected cells were treated
with SNP and NOC-12, which served as apoptosis posi-
tive controls, and cell viability was assessed by trypan
blue dye exclusion.
RNA isolation and real-time PCR assays
Total RNA was isolated from chondrocytes using Invi-
sorb Mini Kit (Invitek, Berlin, Germany), following
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manufacturer’s instructions. Whole RNA was treated
with DNase (Invitrogen), and its concentration was
determined by spectrophotometry. 1 μg of RNA from
each sample was reverse-transcribed in a final volume of
20 μL using the Transcriptor First Strand cDNA Synth-
esis Kit (Roche Applied Science). cDNA synthesis was
performed at 55°C for 30 minutes followed by a final
step of 5 minutes at 85°C for inactivating the reverse
transcriptase. Tubes were finally stored at -20°C until
PCR analyses.
Primers for HSP90B and HPRT1 (housekeeping gene)
were intron-spanning designed using the Universal
Probe Library tool available at Roche website (http://
www.roche-applied-science.com). Primer sequences were
as follows: HSP90B forward, 5’-cgttgctcactattacgta-
taatcct-3’; HSP90B reverse, 5’-tgcctgaaaggcaaaagtct-3’
(108 bp product); HPRT1 forward, 5’-tgaccttgatttattttg-
catacc-3’; HPRT1 reverse, 5’-cgagcaagacgttcagtcct-3’
(102 pb product).
Real-time PCR was performed in a LightCycler 480
instrument (Roche Applied Science), with 20 μL reac-
tions containing 10 μL LightCycler 480 SYBR Green I
Master, 7 μL bidistilled water, 0.5 μL (0.5 μM) each pri-
mer and 2 μL cDNA as PCR template. Cycling para-
meters were 95°C for 10 minutes to activate DNA
polymerase, followed by 45 cycles of 95°C for 10 sec-
onds, 60°C for 10 seconds and a final extension of 72°C
for 10 seconds. Detection of fluorescence was carried
out at the end of each extension step. After amplifica-
tion, a melting curve was acquired by heating to 95°C
for 5 seconds, cooling to 70°C for 1 minute and slowly
heating to 95°C with a continuous fluorescence data col-
lection of 10 acquisitions per°C.
PCR data were analyzed using REST (Relative Expres-
sion Software Tool) software, which provides statistical
information suitable for comparing groups of treated
versus untreated samples while taking into account
issues of reaction efficiency and reference gene
normalisation.
Indirect immunofluorescence
Chondrocytes were seeded at 5 × 104 cells per chamber
in an 8-chamber slide. Cytokine stimulation was carried
out on the chambers with IL1-b (5 ng/ml) or TNF-a
(10 ng/ml) for 48 h. Then, media was removed and cells
were fixed with acetone for 10 minutes at 4°C. After
washing with PBS, anti-Hsp90b primary antibodies were
applied at 1:50 dilution in PBS, and cells were incubated
overnight in a humidified box at 4°C. After further
washing, a FITC-conjugated anti-goat secondary anti-
body was used at 1:20 dilution for 1 h. Fluorescence
microscopy was carried out in a Leica DMLS micro-
scope. Quantification of the emitted fluorescence was
performed with AnalySIS 5.0 software (Olympus
Biosystems, Hamburg, Germany). Nuclei staining was
performed with 4,6-dianidino-2-phenylindole dihy-
drochloride (DAPI, 2 mg/mL) for 30 minutes at 37°C.
Determination of nitric oxide levels by nitrite
quantification
For the evaluation of nitric oxide production by chon-
drocytes, 5 × 104 cells were placed onto culture 96-well
plates and allowed to adhere for 24 h. All conditions
were set by duplicate. Nitric oxide production was sti-
mulated by the addition of 5 ng/ml IL-1b, and the
Hsp90 inhibitors Geldanamycin (GA) and Novobiocin
(NB) (Alexis Biochemicals, Lausen, Switzerland) were
added at 1, 10, 25 and 50 nM (GA), or 100, 500 and
1000 μM (NB). Then, supernatants were collected and
total nitrite released in cell culture medium was mea-
sured by the Griess method [11], using sodium nitrite as
standard. Data were expressed as μM nitrites (NO2
-) per
number of cells per time.
Statistical analysis
The data are expressed as the mean (SEM) from n
determinations or as representative results, as indicated.
The statistical software program, SPSS, was used to per-
form the analysis of variance. Differences were consid-
ered to be significant at p < 0.05.
Results
IL-1b and TNF-a increase the expression of Hsp90b in OA
chondrocytes
In a previous study [4] performed by a gel-based pro-
teomic analysis, we detected the beta isoform of the
chaperone Hsp90 (Hsp90b) as significantly increased in
OA cells (4.52-fold). OA cartilage is characterized by
increases of the catabolic program which are induced
by proinflammatory stimuli. Therefore, to further
investigate the putative positive modulators of Hsp90b
in OA, we now tested if the presence of proinflamma-
tory cytokines such as Interleukin-1b (IL-1b) or
Tumor Necrosis Factor-a (TNF-a) could have any
effect on the amount of this protein in cultured nor-
mal chondrocytes. We stimulated the cells for 24 or 48
h with 5 ng/ml IL-1b or 10 ng/ml TNF-a. As shown
in the indirect immunofluorescence images that are
illustrated in Figure 1A, both cytokines were capable
of increasing Hsp90b abundance in the cytoplasm of
cultured chondrocytes. These results suggest a role of
Hsp90b in mediating the cellular response against
those inflammatory processes, driven by IL-1b, that
participate in OA pathogenesis.
One of the reported consequences of the stimulation
of articular chondrocytes by inflammatory cytokines is
the increase in nitric oxide synthesis from these cells
[12]. To further investigate if nitric oxide has any direct
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effect on Hsp90b protein abundance, we also carried out
indirect immunofluorescence analyses after stimulating
the cells with different NO donors. With this aim, we
treated the chondrocytes with 0.5 to 2 mM NOC-12 or
SNP for 24 hours. As shown in Figure 1B, both NO
donors increase Hsp90b abundance in chondrocytes,
being this increase higher with SNP.
The immunofluorescence results were confirmed with
a more quantitative assay. We performed Western blot
tests on whole chondrocyte extracts obtained from cells
that were treated for 48 h with the different stimuli.
The blots were densitometrically analyzed, being their
intensities normalized against a housekeeping protein,
a-tubulin. As shown in Figure 1C, all of the studied
compounds increase Hsp90b protein expression in
chondrocytes, from 1.31-fold (IL-1b) to 1.76-fold (SNP).
Hsp90b inhibition reduces NO synthesis in chondrocytes
To investigate if Hsp90b might participate in NO signal-
ling in chondrocytes and the possible role of this
chaperone in their response after cytokine stimulation,
we measured nitrite production in the supernatants of
chondrocytes treated with the cytokine IL-1b and differ-
ent amounts of the well-known Hsp90b inhibitors
Novobiocin (NB) and Geldanamycin (GA) [13]. We
observed with both inhibitors a dose-dependent decrease
of those high nitrite levels induced by the cytokine, from
37.28 ± 1.9 down to 8.85 ± 0.23 μM NO2
- per 5 × 104
cells per 48 h of production, being the differences statis-
tically significant (all of them with p < 0.05) with GA
(Figures 2A and 2B).
We also exposed the cells to IL-1b and the Hsp90b
inhibitor GA for their phase contrast microscope obser-
vation. The cellular morphology of these cells (exempli-
fied in Figure 2C) reveals those striking morphological
changes caused by the cytokine in cultured chondro-
cytes, and how the addition of the Hsp90b inhibitor GA
has no effect on cellular viability (as determined by Try-
pan blue dye exclusion) and even restores the normal
chondrocyte morphology in IL1b-treated cells.
Figure 1 Hsp90b is modulated by proinflammatory cytokines and NO donors in chondrocytes. A) and B) Indirect immunofluorescence
(IFI) analyses showing: A) the IL-1b- and TNFa- dependent increase of Hsp90b protein level; B) the increase of Hsp90b (green) after cellular
stimulation with NOC-12 and SNP. Cellular nuclei, stained with DAPI, display a blue colour. Scale bars correspond to 100 μm. C) Western blot
analysis on whole chondrocyte extracts stimulated for 48 h. a-Tubulin was used as loading control for normalization purposes. A representative
image of the blots is shown in the left, together with the semiquantitative data obtained by densitometric analysis of the blots and normalized
with the tubulin signal (on the right). Data are expressed as arbitrary volume units, and represent the mean (±SE) of four independent
experiments (*, p < 0.05 and **, p < 0.01 vs basal).
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Figure 2 Hsp90b is involved in the synthesis of NO caused by IL-1b stimulation of chondrocytes. Effect of Hsp90 inhibitors Geldanamycin
(GA) (A) and Novobiocin (NB) (B) on the production of nitrites by IL-1b-treated chondrocytes. Data are expressed as mM of nitrites present in the
supernatant, and represent the mean (±SE) of three independent experiments in triplicate (*, p < 0.05; **, p < 0.01 and ***, p < 0.005 vs basal).
C) Phase contrast microscopy images illustrate how the Hsp90 inhibitor Geldanamicyn (GA) does not affect cellular viability and counteracts the
morphological modifications caused by IL-1b in cultured chondrocytes. Scale bars correspond to 100 μm. D) Cell viability of chondrocytes
treated with IL-1b and Novobiocin, measured by the MTS assay.
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Finally, a significant NO accumulation was observed
with NB treatment alone, which rises dose-dependently
from 11.2 μM NO (with 100 μM NB) to 22.1 μM (with
1 mM NB). Therefore, we performed a quantitative
assay of the chondrocyte viability under these conditions
using the MTS reagent. As shown in Figure 2D, no sig-
nificant reduction in cell viability is observed after treat-
ment with up to 100 μM NB, whereas the presence of
the inhibitor at 1 mM concentration decreases chondro-
cyte viability a 35% in average.
Hsp90 inhibitors prevent cellular death caused by NO
donors in chondrocytes
It is well known that NO regulates catabolic processes
in chondrocytes, and can induce apoptosis [14]. Taking
into account the effect of Hsp90 inhibitors on NO pro-
duction from chondrocytes, we tested if these com-
pounds may exert any effect on the cellular death
induced by NO donors. We stimulated the cells with
NOC-12 (0.5 mM, Figure 3A) and SNP (1 mM, Figure
3B) alone or in combination with the Hsp90 inhibitors
GA or NB, and the apoptosis levels were measured by
flow cytometry. As shown in Figure 3, treating the
chondrocytes with NOC-12 or SNP provokes the pre-
sence of a 38.31 ± 19.6% and 52.07 ± 15.4% of apoptotic
cells in the population, respectively. Addition of Hsp90
inhibitors reduces the cellular death down to a 9.02 ±
5.3% (NOC-12 with GA).
Specific Hsp90b silencing diminishes the cellular death
induced by NO donors
Hsp90 inhibitors have shown to be related with a num-
ber of cellular processes, being in some cases rather
unspecific. In order to confirm if the results previously
demonstrated are specific of Hsp90b inhibition, we
determined whether Hsp90b silencing affected the cellu-
lar death levels of chondrocytes exposed to NO donors.
With this aim, chondrocytes were transfected with
Figure 3 Hsp90b inhibitors prevent chondrocyte apoptosis induced by nitric oxide donors. Flow cytometry analysis of chondrocytes
treated with NOC-12 (A), SNP (B) and the Hsp90b inhibitors GA and NB. Apoptosis is expressed as percentage of hypodiploid nuclei present in
the population, and represent the mean (±SE) of four independent experiments by triplicate. Error bars indicate standard deviation of the mean
(*, p < 0.05 vs basal).
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Hsp90b siRNA. Output of the silencing on Hsp90b tran-
scriptional (A) and protein (B) levels are shown in Fig-
ure 4. Gene silencing with siRNA provoked a 17-fold
decrease of Hsp90b gene expression, as demonstrated
by real-time PCR (Figure 4A), and more than a 2-fold
reduction of protein abundance in chondrocytes (Figure
4B). Transfected cells (n = 3) were then cultured and
treated for 24 h in the presence or absence of 1 mM
SNP. Apoptosis levels were determined by flow cytome-
try and ELISA. Data obtained revealed that Hsp90b
silencing reduces the cellular death provoked by SNP in
chondrocytes 2.4-fold, when determined by flow cyto-
metry (from 17.41 ± 8.9% to 7.36 ± 4.7% hypodiploid
nuclei, n = 3, p < 0.05, Figure 5A), and 3.2-fold when
determined by ELISA (from 1.43 ± 0.14 to 0.45 ± 0.20
absorbance units, n = 3, p < 0.01, Figure 5B). Similar
results were obtained with NOC-12, although they were
not statistically significant with the number of experi-
ments analyzed (data not shown).
Discussion
We previously showed the increased abundance of the
chaperone Hsp90b in OA chondrocytes grown in mono-
layer culture, when compared to normal cells [4]. In this
work, our aim was to gain insight into the modulation
of Hsp90b in human articular chondrocytes and the
possible outputs of an increase of this chaperone in this
type of cells.
The cytosolic Hsp90b is a calcium-binding protein
that belongs to the family of 90 kDa protein chaperones
[15]. It is involved in the folding, activation and assem-
bly of several proteins. Our finding of an increase of this
protein in osteoarthritic chondrocytes, along with other
chaperones such as Grp78 or Grp94 [4], points to an
essential role of the stress response in OA pathogenesis
that should be studied in more detail. Therefore, we
have now demonstrated that the presence of Hsp90b in
chondrocytes is increased after stimulating the cells with
proinflammatory cytokines involved in cartilage destruc-
tion, such as IL-1b or TNF-a, and also by NO-induced
stress.
In contrast to our data, Hsp90b has been recently
found to be a novel regulatory factor of MMP-13
expression in osteoarthritic chondrocytes [16]. In this
work, authors describe how silencing Hsp90b signifi-
cantly increased MMP-13, which indicates a negative
modulation driven by the chaperone. Moreover, they
show how the addition of IL-1b decreased Hsp90b pro-
duction. These results are opposed to our data and
those by Boehm et al., who previously reported that
Hsp90 inhibition (of both a and b forms) blocked IL-
1b-induced up-regulation of MMP-13 in equine articu-
lar chondrocytes [17]. Moreover, most recently Kimura
et al. identified a promising compound for OA therapy
that achieved the above mentioned MMP-13 production
blockage [18], and subsequently determined that this
compound acts as a client-selective Hsp90 inhibitor
[19]. This divergence might be explained by the different
quantities of IL-1b employed to induce metalloprotease
production, as Fan et al. use 100-fold less amount of
cytokine than the others.
Moreover, the use of chemical inhibitors can be con-
troversial. Traditional Hsp90 inhibitors have been exten-
sively studied for oncology therapy [20], and small
molecule inhibitors of Hsp90 have been described to
affect inflammatory disease pathways in models of rheu-
matoid arthritis [21]. Both Geldanamycin (GA), which
binds to the N-terminal ATP-binding site of the protein
[22], and Novobiocin (NB), which binds to a second
ATP-binding site on the C-terminal domain [23] are
Figure 4 Effect of gene silencing on Hsp90b transcription and protein abundance. Chondrocytes were transfected with the specific
Hsp90b small interfering RNA. Total RNA and cellular proteins were extracted from control and transfected cells. A) Real-time PCR assays confirm
the decrease of HSP90B gene expression in the presence of the siRNA. Data are expressed relative to gene expression without siRNA (*, p <
0.0001; n = 3). B) Representative western blot that illustrates the effect of siHsp90b at the protein level. Semi-quantitative data, obtained by
densitometric analysis of the blots and normalization of each lane using a-tubulin signal, are shown at the right (*, p < 0.01; n = 3).
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global Hsp90 inhibitors: that is, they are known to block
both Hsp90 isoforms (a and b), which share about 80%
homology, and maybe other factors. In this sense, GA
has proven to inhibit the ATPase activity of TRAP1, a
mitochondrial homolog of Hsp90 [24] that was recently
identified as increased in OA mitochondria [25]. In the
present work, we have employed these compounds to
screen the effects of low amounts of this chaperone in
chondrocytes subjected to cytokine and NO stress in an
attempt to mimic an OA status. Then, in order to
search for the specific effect of Hsp90b, we have
silenced this b isoform with siRNA and can therefore
conclude that this protein really participates in the NO-
induced apoptotic process of chondrocytes.
Evidence suggests that Hsp90 is an allosteric enhancer
of inducible nitric oxide synthase (iNOS) activity, and
that binding of Hsp90 to this enzyme is required for
iNOS activity [26]. IL-1b stimulates cartilage ECM
degradation in OA, in part through up-regulation of
iNOS, which increases NO production [27,28]. NO has
been shown to regulate catabolic reactions in chondro-
cytes, being able to induce apoptosis [14]. A number of
NO donors have been described to reduce respiration
and ATP generation, which suggests a contribution to
cartilage ECM loss and mineralization [29]. With this
background, the decreased synthesis of NO that we
observed after Hsp90 inhibition is an interesting positive
outcome that points to Hsp90 as putative target for OA.
Moreover, Hsp90 plays a well-known role as major
repressor of heat shock transcription factor HSF1 [30],
whose activation increases the synthesis of several cyto-
protective proteins [31]. Inhibition of Hsp90 (and also
stress or heat shock conditions) releases HSF1 from the
Hsp90 complex, which results in its activation and trans-
location to the nucleus, where it initiates a protective
response with a transcriptional program linked to cellular
adaptation and survival [32], and manifested in the pro-
duction of proteins with anti-apoptotic or protein folding
functions. As a proof of act, it has been demonstrated
very recently that HSF1 inhibits H2O2-induced apoptosis
via down-regulation of reactive oxygen species [33]. With
the same reasoning, it is not tempting to speculate that
HSF1 activation might also drive the protective mechan-
isms working against NO-induced apoptosis when
Hsp90b is inhibited. All these data shed light again on
the usefulness of Hsp90 as therapeutic target for OA.
Given the broad spectrum of cellular roles played by
this chaperone, the question arises as to whether Hsp90
global inhibition would be efficient in the treatment of
OA. Recent investigations such as those reported above
[19], which employ client-selective Hsp90 inhibitors,
might have the highest therapeutic potential, in an
attempt to reduce their pleiotropic abilities and drive
them to a specific area of Hsp90 effects, such as those
related with NO synthesis and protecting chondrocyte
from apoptosis.
Conclusions
The present work depicts the effect of Hsp90 inhibition
in the modulation of NO production by human OA
chondrocytes, and also in protecting these cells from
NO-provoked death. Additional evaluation is needed to
support the therapeutic use of selective Hsp90 inhibitors
in OA, and further studies on the role of Hsp90 in
diverse OA-related pathogenesis processes would help
to attain this objective.
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